Priovant Therapeutics announced the publication of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE